|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bhatt JR and FinelliI A: Landmarks in the
diagnosis and treatment of renal cell carcinoma. Nat Rev Urol.
11:517–525. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kamps R, Brandao RD, Bosch BJ, Paulussen
AD, Xanthoulea S, Blok MJ and Romano A: Next-generation sequencing
in oncology: Genetic diagnosis, risk prediction and cancer
classification. Int J Mol Sci. 18:E3082017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mirza Z, Schulten HJ, Farsi HM,
Al-Maghrabi JA, Gari MA, Chaudhary AG, Abuzenadah AM, Al-Qahtani MH
and Karim S: Impact of S100A8 expression on kidney cancer
progression and molecular docking studies for kidney cancer
therapeutics. Anticancer Res. 34:1873–1884. 2014.PubMed/NCBI
|
|
6
|
Brugarolas J: Molecular genetics of
clear-cell renal cell carcinoma. J Clin Oncol. 32:1968–1976. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Alpi AF, Chaugule V and Walden H:
Mechanism and disease association of E2-conjugating enzymes:
Lessons from UBE2T and UBE2L3. Biochem J. 473:3401–3419. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Machida YJ, Machida Y, Chen Y, Gurtan AM,
Kupfer GM, D'Andrea AD and Dutta A: UBE2T is the E2 in the fanconi
anemia pathway and undergoes negative autoregulation. Mol Cell.
23:589–596. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alpi A, Langevin F, Mosedale G, Machida
YJ, Dutta A and Patel KJ: UBE2T, the fanconi anemia core complex,
and FANCD2 are recruited independently to chromatin: A basis for
the regulation of FANCD2 monoubiquitination. Mol Cell Biol.
27:8421–8430. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Richman KA, Lach FP, Abhyankar A, Donovan
FX, Sanborn EM, Kennedy JA, Sougnez C, Gabriel SB, Elemento O,
Chandrasekharappa SC, et al: Deficiency of UBE2T, the E2 ubiquitin
ligase necessary for FANCD2 and FANCI ubiquitination, causes FA-T
subtype of fanconi anemia. Cell Rep. 12:35–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mamrak NE, Shimamura A and Howlett NG:
Recent discoveries in the molecular pathogenesis of the inherited
bone marrow failure syndrome fanconi anemia. Blood Rev. 31:93–99.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hira A, Yoshida K, Sato K, Okuno Y,
Shiraishi Y, Chiba K, Tanaka H, Miyano S, Shimamoto A, Tahara H, et
al: Mutations in the gene encoding the E2 conjugating enzyme UBE2T
cause fanconi anemia. Am J Hum Genet. 96:1001–1007. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Alter BP: Fanconi anemia and the
development of leukemia. Best Pract Res Clin Haematol. 27:214–221.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hu W, Xiao L, Cao C, Hua S and Wu D: UBE2T
promotes nasopharyngeal carcinoma cell proliferation, invasion, and
metastasis by activating the AKT/GSK3β/β-catenin pathway.
Oncotarget. 7:15161–15172. 2016.PubMed/NCBI
|
|
15
|
Liu LP, Yand M, Peng QZ, Li MY, Zhang YS,
Guo YH, Chen Y and Bao SY: UBE2T promotes hepatocellular carcinoma
cell growth via ubiquitination of p53. Biochem Biophys Res Commun.
493:20–27. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wen M, Kwon Y, Wang Y, Mao JH and Wei G:
Elevated expression of UBE2T exhibits oncogenic properties in human
prostate cancer. Oncotarget. 6:25226–25239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Y, Leng H, Chen H, Wang L, Jiang N,
Hua X and Yu B: Knockdown of UBE2T inhibits osteosarcoma cell
proliferation, migration, and invasion by suppressing the PI3K/Akt
signaling pathway. Oncol Res. 24:361–369. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Luo C, Yao Y, Yu Z, Zhou H, Guo L, Zhang
J, Cao H, Zhang G, Li Y and Jiao Z: UBE2T knockdown inhibits
gastric cancer progression. Oncotarget. 8:32639–32654.
2017.PubMed/NCBI
|
|
19
|
Gong YQ, Peng D, Ning XH, Yang XY, Li XS,
Zhou LQ and Guo YL: UBE2T silencing suppresses proliferation and
induces cell cycle arrest and apoptosis in bladder cancer cells.
Oncol Lett. 12:4485–4492. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ueki T, Park JH, Nishidate T, Kijima K,
Hirata K, Nakamura Y and Kataqiri T: Ubiquitination and
downregulation of BRCA1 by ubiquitin-conjugating enzyme E2T
overexpression in human breast cancer cells. Cancer Res.
69:8752–8760. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ramaekers CH, van den Beucken T, Meng A,
Kassam S, Thoms J, Bristow RG and Wouters BG: Hypoxia disrupts the
fanconi anemia pathway and sensitizes cells to chemotherapy through
regulation of UBE2T. Radiother Oncol. 101:190–197. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Perez-pena J, Corrales-sanchez V, Amir E,
Pandiella A and Ocana A: Ubiquitin-conjugating enzyme E2T (UBE2T)
and denticleless protein homolog (DTL) are linked to poor outcome
in breast and lung cancers. Sci Rep. 7:175302017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hao J, Xu A, Xie X, Hao J, Tian T, Gao S,
Xiao X and He D: Elevated expression of UBE2T in lung cancer tumors
and cell lines. Tumour Biol. 29:195–203. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lopez-Beltran A, Scarpelli M, Montironi R
and Kirkali Z: 2004 WHO classification of the renal tumors of the
adults. Eur Urol. 49:798–805. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen T, You Y, Jiang H and Wang ZZ:
Epithelial-mesenchymal transition (EMT): A biological process in
the development, stem cell differentiation, and tumorigenesis. J
Cell Physiol. 232:3261–3272. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Figiel S, Vasseur C, Bruyere F, Rozet F,
Maheo K and Fromont G: Clinical significance of
epithelial-mesenchymal transition markers in prostate cancer. Hum
Pathol. 61:26–32. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Scanlon CS, Van Tubergen EA, Inglehart RC
and D'Silva NJ: Biomarkers of epithelial-mesenchymal transition in
squamous cell carcinoma. J Dent Res. 92:114–121. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tian T, Li XY and Zhang JH: mTOR signaling
in cancer and mTOR inhibitors in solid tumor targeting therapy. Int
J Mol Sci. 20:7552019. View Article : Google Scholar :
|
|
30
|
Faes S and Dormond O: PI3K and AKT:
Unfaithful partners in cancer. Int J Mol Sci. 16:21138–21152. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Berquist SW, Yim K, Ryan ST, Patel SH,
Eldefrawy A, Cotta BH, Bradshaw AW, Meagher MF, Bindayi A, McKay
RR, et al: Systemic therapy in the management of localized and
locally advanced renal cell carcinoma: Current state and future
perspectives. Int J Urol. Apr 3–2019.(Epub ahead of print).
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wiechno P, Kucharz J, Sadowska M,
Michalski W, Sikora-Kupis B, Jonska-Gmyrek J, Poniatowska G,
Nietupski K, Ossolinski K and Demkow T: Contemporary treatment of
metastatic renal cell carcinoma. Med Oncol. 35:1562018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hsieh JJ, Purdue MP, Signoretti S, Swanton
C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal
cell carcinoma. Nat Rev Dis Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
D'Avella C, Abbosh P, Pal SK and Geynisman
DM: Mutations in renal cell carcinoma. Urol Oncol. Nov
23–2018.(Epub ahead of print). View Article : Google Scholar
|
|
35
|
Yu H, Xiang P, Pan Q, Huang Y, Xie N and
Zhu W: Ubiquitin-conjugating enzyme E2T is an independent
prognostic factor and promotes gastric cancer progression. Tumour
Biol. 37:11723–11732. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Brabletz T, Kalluri R, Nieto MA and
Weinberg RA: EMT in cancer. Nat Rev Cancer. 18:128–134. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dimitrova V and Arcaro A: Targeting the
PI3K/Akt/mTOR signaling pathway in medulloblastoma. Curr Mol Med.
15:82–93. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cargnello M, Tcherkezian J and Roux PP:
The expanding role of mTOR in cancer cell growth and proliferation.
Mutagenesis. 30:169–176. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Manfredi GI, Dicitore A, Gaudenzi G,
Caraglia M, Persani L and Vitale G: PI3K/Akt/mTOR signaling in
medullary thyroid cancer: A promising molecular target for cancer
therapy. Endocrine. 48:363–370. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xie C, Powell C, Yao M, Wu J and Dong Q:
Ubiquitin-conjugating enzyme E2C: A potential cancer biomarker. Int
J Biochem Cell Biol. 47:113–117. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang R, Song Y, Liu X, Wang Q, Wang Y, Li
L, Kang C and Zhang Q: UBE2C induces EMT through Wnt/βcatenin and
PI3K/Akt signaling pathways by regulating phosphorylation levels of
aurora-a. Int J Oncol. 50:1116–1126. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jin Y, Xu K, Chen Q, Wang B, Pan J, Huang
S, Wei Y and Ma H: Simvastatin inhibits the development of
radioresistant esophageal cancer cells by increasing the
radiosensitivity and reversing EMT process via the PTEN-PI3K/AKT
pathway. Exp Cell Res. 362:362–369. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rumman M, Jung KH, Fang Z, Yan HH, Son MK,
Kim SJ, Kim J, Park JH, Lim JH, Hong S and Hong SS: HS-173, a novel
PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer.
Oncotarget. 7:78029–78047. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang GW, Tian X, Li Y, Wang ZQ, Li XD and
Zhu CY: Down-regulation of ETS2 inhibits the invasion and
metastasis of renal cell carcinoma cells by inducing EMT via the
PI3K/Akt signaling pathway. Biomed Pharmacother. 104:119–126. 2018.
View Article : Google Scholar : PubMed/NCBI
|
